Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com
Dallas, TX (PRWEB) May 26, 2015 -- The report “Liver Failure – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Liver Failure. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2015 pipeline review of Liver Failure with 22 market data tables and 14 figures, spread across 65 pages is available at http://www.rnrmarketresearch.com/liver-failure-pipeline-review-h1-2015-market-report.html .
Companies discussed in this Pheochromocytoma – Pipeline Review, H1 2015 report include Alfact Innovation, Conatus Pharmaceuticals Inc., Digna Biotech, S.L., Grifols, S.A., Immune Pharmaceuticals, Ltd., Ventria Bioscience.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Drug Profiles mentioned in this report are albumin (human), ALF-5755, BI-78D3, cardiotrophin-1, Cell Therapy for Liver Failure, emricasan, F-573, ImmuneSafe, Oligonucleotide for Liver Failure, Recombinant Protein for Liver Failure, Recombinant Protein to Inhibit JNK for Liver Failure, RNAi Oligonucleotides to Inhibit MAP Kinase 4 for Liver Failure, Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure, Stem Cell Therapy for Liver Failure, VEN-100. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=375209 (This is a premium report priced at US$2000 for a single user License)
Featured News & Press Releases covered by this report includes: Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan; Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan; Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting; Apr 02, 2013: ALF-5755 phase II completion; Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure; Sep 21, 2011: Digna Biotech Receives FDA Orphan Drug Status For Cardiotrophin-1 For Acute Liver Failure Treatment; May 06, 2011: ALF-5755 phase II extends to germany; May 05, 2011: Alfact Innovation Receives Orphan Drug Designation For ALF-5755 From FDA; Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I; Mar 10, 2011: Digna Biotech And Biotecnol Announce Spanish Approval For Phase I Clinical study Of Cardiotrophin I.
List of Tables
Number of Products under Development for Liver Failure, H1 2015 8
Number of Products under Development for Liver Failure - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Comparative Analysis by Unknown Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Liver Failure - Pipeline by Alfact Innovation, H1 2015 17
Liver Failure - Pipeline by Conatus Pharmaceuticals Inc., H1 2015 18
Liver Failure - Pipeline by Digna Biotech, S.L., H1 2015 19
Liver Failure - Pipeline by Grifols, S.A., H1 2015 20
Liver Failure - Pipeline by Immune Pharmaceuticals, Ltd., H1 2015 21
Liver Failure - Pipeline by Ventria Bioscience, H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 27
Number of Products by Stage and Route of Administration, H1 2015 29
Number of Products by Stage and Molecule Type, H1 2015 31
Liver Failure Therapeutics - Recent Pipeline Updates, H1 2015 51
Liver Failure - Dormant Projects, H1 2015 56
List of Figures
Number of Products under Development for Liver Failure, H1 2015 8
Number of Products under Development for Liver Failure - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Top 10 Targets, H1 2015 24
Number of Products by Stage and Top 10 Targets, H1 2015 24
Number of Products by Top 10 Mechanism of Actions, H1 2015 26
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 26
Number of Products by Top 10 Routes of Administration, H1 2015 28
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 29
Number of Products by Top 10 Molecule Types, H1 2015 30
Number of Products by Stage and Top 10 Molecule Types, H1 2015 31
Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article